{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T18:34:16Z","timestamp":1782930856939,"version":"3.54.5"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T00:00:00Z","timestamp":1639180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.clml.2021.12.009","type":"journal-article","created":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T17:05:20Z","timestamp":1639415120000},"page":"e405-e413","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Real-World Evidence of Epidemiology and Clinical Outcomes in Multiple Myeloma, Findings from the Registry of Hemato-Oncologic Malignancies in Colombia, Observational Study"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6507-4041","authenticated-orcid":false,"given":"Virginia","family":"Abello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2778-164X","authenticated-orcid":false,"given":"William Armando","family":"Mantilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Idrobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Lucia","family":"Sossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Antonio","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Pena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo Enrique","family":"Quintero-Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Munevar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenny","family":"Galvez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Henao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rigoberto","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Domingo","family":"Saavedra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6748-6971","authenticated-orcid":false,"given":"Lina Mar\u00eda","family":"Gaviria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Osuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.12.009_bib0001","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.clml.2020.11.020","article-title":"Impact of Socioeconomic Characteristics and Comorbidities on Therapy Initiation and Outcomes of Newly Diagnosed Multiple Myeloma: Real-World Data From a Resource-Constrained Setting","volume":"21","author":"Vargas-Serafin","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2021.12.009_bib0002","series-title":"Cancer Fact Sheet","year":"2020"},{"key":"10.1016\/j.clml.2021.12.009_bib0003","unstructured":"Cifras y estimaciones de c\u00e1ncer en el mundo Globocan e IARC. The Global Cancer Observatory 2018 [Internet]. 2018."},{"key":"10.1016\/j.clml.2021.12.009_bib0004","unstructured":"Estimated number of incident cases from 2018 to 2040, all cancers, both sexes, all ages Available at: https:\/\/gco.iarc.fr\/tomorrow\/graphic-bar? type=1&type_sex=0&mode=population&sex=0&populations=170&cancers=39&age_group=value&apc_male=0&apc_female=0&single_unit=500000&print=0#collapse-group-0-1: International Agency for Research of Cancer; 2020"},{"key":"10.1016\/j.clml.2021.12.009_bib0005","unstructured":"DANE. Causas de muerte en el 2018 Available at: http:\/\/systema74.dane.gov.co\/bincol\/RpWebEngine.exe\/Portal?BASE=DEFOC2018\u3008=esp:DANE; 2018"},{"key":"10.1016\/j.clml.2021.12.009_bib0006","unstructured":"WHO classification of Tumors of Haematopoietic and Lymphoid Tissues 2017."},{"key":"10.1016\/j.clml.2021.12.009_bib0007","doi-asserted-by":"crossref","first-page":"128","DOI":"10.17533\/udea.rfnsp.11515","article-title":"Registros poblacionales de c\u00e1ncer: avances en Colombia, Chile y Brasil","volume":"31","author":"Arias","year":"2013","journal-title":"Rev Fac Nac Salud P\u00fablica"},{"key":"10.1016\/j.clml.2021.12.009_bib0008","unstructured":"Cancer IAfRi. Globocan Colombia 2020 Available at: https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/170-colombia-fact-sheets.pdf: Organizaci\u00f3n Mundial de la Salud; 2020"},{"key":"10.1016\/j.clml.2021.12.009_bib0009","unstructured":"Fondo Colombiano de Enfermedades de Alto Costo CdACC. Situaci\u00f3n del c\u00e1ncer en la pobla ci\u00f3n adulta atendida en el SGSSS de Colombia 2019. 2019."},{"issue":"1","key":"10.1016\/j.clml.2021.12.009_bib0010","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1182\/blood-2019-124936","article-title":"Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States","volume":"134","author":"Binder","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.12.009_bib0011","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00277-016-2866-9","article-title":"Observational study of multiple myeloma in Latin America","volume":"96","author":"Hungria","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2021.12.009_bib0012","doi-asserted-by":"crossref","first-page":"E538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.clml.2021.12.009_bib0013","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.12.009_bib0014","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/ajh.25797","article-title":"Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75\u2009years","volume":"95","author":"Belotti","year":"2020","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2021.12.009_bib0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1182\/blood-2020-142376","article-title":"Multiple Myeloma Mortality Incidence Prevalence of Disease - Mmy Mind Study","volume":"136","author":"Mart\u00ednez","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.12.009_bib0016","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","article-title":"VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial","volume":"127","author":"Moreau","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.12.009_bib0017","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1038\/leu.2015.80","article-title":"Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma","volume":"29","author":"Mai","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.12.009_bib0018","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study","volume":"120","author":"Rosi\u00f1ol","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.12.009_bib0019","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/qjmed\/hcm077","article-title":"Multiple myeloma: Causes and consequences of delay in diagnosis","volume":"100","author":"Kariyawasan","year":"2007","journal-title":"QJM"},{"key":"10.1016\/j.clml.2021.12.009_bib0020","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1002\/cam4.1347","article-title":"Epidemiology of multiple myeloma in 17 Latin American countries: An update","volume":"7","author":"Curado","year":"2018","journal-title":"Cancer Medicine"},{"key":"10.1016\/j.clml.2021.12.009_bib0021","doi-asserted-by":"crossref","first-page":"165","DOI":"10.21115\/JBES.v10.n2.p165-171","article-title":"Unmet needs in multiple myeloma in Brazil from physicians\u2019 perspective \u2013 barriers in quality of life and disease management","volume":"10","author":"Maiolino","year":"2018","journal-title":"Jornal Brasileiro de Economia da Sa\u00fade"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2021.12.009_bib0022","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1182\/blood-2019-127625","article-title":"An institutional retrospective study on recognizing the delay in multiple myeloma diagnosis","volume":"134","author":"Ghalehsari","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2021.12.009_bib0023","doi-asserted-by":"crossref","DOI":"10.2217\/ijh-2018-0014","article-title":"Methods for reducing delays in the diagnosis of multiple myeloma","volume":"8","author":"Koshiaris","year":"2019","journal-title":"International Journal of Hematologic Oncology"},{"key":"10.1016\/j.clml.2021.12.009_bib0024","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.12.009_bib0025","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2021.12.009_bib0026","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.3390\/cancers12123497","article-title":"Risk and Response-Adapted Treatment in Multiple Myeloma","volume":"12","author":"Cazaubiel","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2021.12.009_bib0027","first-page":"5811","article-title":"High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: a report of the Polish Myeloma Study Group","volume":"18","author":"Hus","year":"2019","journal-title":"Oncol Lett"},{"key":"10.1016\/j.clml.2021.12.009_bib0028","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0889-8588(05)70419-6","article-title":"Standard therapy versus autologous transplantation in multiple myeloma","volume":"11","author":"Attal","year":"1997","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clml.2021.12.009_bib0029","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.12.009_bib0030","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2004-02-0408","article-title":"Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial","volume":"104","author":"Palumbo","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.12.009_bib0031","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.12.009_bib0032","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.12.009_bib0033","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/leu.2016.381","article-title":"Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis","volume":"31","author":"Gay","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.12.009_bib0034","doi-asserted-by":"crossref","first-page":"5614","DOI":"10.1182\/blood.V126.23.5614.5614","article-title":"Real-World Data on Multiple Myeloma: A Prospective National Registry in Uruguay","volume":"126","author":"Riva","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.12.009_bib0035","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1016\/j.clml.2018.06.018","article-title":"Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study","volume":"18","author":"Mohty","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2021.12.009_bib0036","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/bmt.2016.361","article-title":"Latin America: the next region for haematopoietic transplant progress","volume":"52","author":"Jaimovich","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2021.12.009_bib0037","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/bjh.16124","article-title":"Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato-Oncology (HOLA) Observational Study, 2008-2016","volume":"188","author":"de Moraes Hungria","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.12.009_bib0038","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1097\/HS9.0000000000000045","article-title":"Long-term Outcomes in Patients With Multiple Myeloma: A Retrospective Analysis of the Dutch Population-based HAematological Registry for Observational Studies (PHAROS)","volume":"2","author":"Verelst","year":"2018","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2021.12.009_bib0039","first-page":"e43","article-title":"Analysis of availability and access of anti- myeloma drugs and impact on the management of multiple myeloma in Latin American countries","volume":"19","author":"E","year":"2018","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2021.12.009_bib0040","doi-asserted-by":"crossref","first-page":"S240","DOI":"10.1016\/S2152-2650(20)30827-2","article-title":"ACHO (Asociaci\u00f3n Colombiana de Hematolog\u00eda y Oncolog\u00eda), RENEHOC researchers. Impact of Insurance Differences in Outcomes in Colombian Patients with Chronic Myeloid Leukemia (CML)","volume":"20","author":"Abello-Polo","year":"2020","journal-title":"Clynical Lymphoma, Myeloma and Leukemia."}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021024782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021024782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T09:40:26Z","timestamp":1726306826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021024782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S2152265021024782"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.12.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Evidence of Epidemiology and Clinical Outcomes in Multiple Myeloma, Findings from the Registry of Hemato-Oncologic Malignancies in Colombia, Observational Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}